An automated drug screening approach gives insight into rare NGLY1 deficiency.
Sometimes, diagnosing and treating an illness is straightforward. Other times, the diagnosis is challenging while the treatment is simple—or vice versa. In the case of a rare disease like NGLY1 Deficiency, both diagnosis and treatment can feel unreachable. The complex challenges of rare diseases prompt outside-the-box approaches—such as the partnership between a rare disease funding body and a fundamental research group. In an article published in G3, Portillo Rodriguez et al. report findings from just such a partnership, outlining a drug screening methodology used to shed light on this rare disease.
N-glycanase 1 (NGLY1) is an enzyme responsible for cleaving sugars from proteins as part of the endoplasmic reticulum-associated degradation (ERAD) pathway, which oversees the breakdown of misfolded proteins. In humans, lack of NGLY1 leads to a condition that baffled clinicians and evaded identification until just a few years ago. NGLY1 Deficiency causes global developmental delay, seizures, floppy body, and an inability to produce tears; fewer than 50 patients with the condition have ever been identified, making research on treatments extremely difficult.
Funding for rare disease research can be hard to come by through standard mechanisms—with so few people affected, scarce research funds are rarely diverted their way. When their daughter Grace was diagnosed with NGLY1 Deficiency, Matt and Kristen Wilsey started the Grace Science Foundation, dedicated to finding a cure for the disease and others like it. In 2017, Grace Science partnered with Perlara, a biotech public benefit corporation (bioPBC) that uses model organisms to discover treatments for rare disease. Their goal is to use high-throughput methodologies in model organisms to identify drugs that could impact the rare disease in question.
The report by Portillo Rodriguez et al. is the first publication to come out of this NGLY1 partnership. The researchers developed an assay that let them efficiently screen a collection of 2,650 compounds for any that might modulate NGLY1-related phenotypes. They first generated a new Drosophila model of NGLY1 Deficiency by introducing a nonsense mutation into Pngl, the fly homolog of NGLY1; this model has a readily identifiable larval size phenotype, which let them perform their screen in 96-well plates with three larvae per well. Each well contained a different drug from the Microsource Spectrum compound library; an automated workflow imaged the plates and quantified the size of the larvae to determine which, if any, of the chemicals modified the mutant phenotype.
The screen produced a single validated hit: 20-hydroxyecdysone (20E), which is an important signaling hormone that drives metamorphosis and molting in arthropods. While 20E is not a good drug candidate for human patients, the implication of the neuroendocrine axis in the pathophysiology of the Drosophila phenotype gives us more information into the mechanism of NGLY1/Pngl than we previously had.
Anything we can learn about the molecular players that contribute to rare disease brings us closer to finding interventions for patients—as does the availability of a validated screening platform. Because model organisms like Drosophila are so amenable to high-throughput screening of whole organism phenotypes, the hope is that approaches like these will bring people with rare diseases one step closer to treatments.
Citation
Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency
Tamy Portillo Rodriguez, Joshua D. Mast, Tom Hartl, Tom Lee, Peter Sand, Ethan O. Perlstein
G3: Genes, Genomes, Genetics July 1, 2018 vol. 8 no. 7 2193-2204;
https://doi.org/10.1534/g3.118.300578
http://www.g3journal.org/content/8/7/2193
Scientific Editor and Programs Manager. Genetics and Molecular Biology PhD. Find me on Twitter: @_sbay
View all posts by Sarah Bay »Read more in
-
Early Career Leadership Spotlight: Julio Molina Pineda
We’re taking time to get to know the members of the GSA’s Early Career Scientist Committees. Join us to learn more about our early career scientist advocates. Julio Molina Pineda Policy and Advocacy University of Arkansas Research Interest My research interests focus on using model organisms to genetically dissect complex traits related to human disease. My…
-
Early Career Leadership Spotlight: Peiwei Chen
We’re taking time to get to know the members of the GSA’s Early Career Scientist Committees. Join us to learn more about our early career scientist advocates. Peiwei Chen Accessibility Subcommittee California Institute of Technology Research Interest Far from a harmonious place, the genome is a battleground, where every bit of DNA fights for inheritance and…
-
#Dros23 GSA Poster Award winners
We are pleased to announce the GSA Poster Award winners from the 64th Annual Drosophila Research Conference! Undergraduate and graduate student members of the GSA were eligible for the awards, and a hard-working team of postdocs volunteered their time as judges. Congratulations to all! Undergraduate Students 1st Place: Sofia Karter Lopez, University of Toronto “Rab11 mediates E-cadherin recycling during…
-
Congratulations to the Fall 2022 DeLill Nasser Awardees!
GSA is pleased to announce the recipients of the DeLill Nasser Award for Professional Development in Genetics for Fall 2022! Given twice a year to graduate students and postdoctoral researchers, DeLill Nasser Awards support attendance at meetings and laboratory courses. The award is named in honor of DeLill Nasser, a long-time GSA supporter and National Science Foundation…
-
New editors join GENETICS, G3 editorial boards
Several new editors are joining the GSA Journals. We’re excited to welcome Ricardo Zayas to the GENETICS editorial board under the Molecular Genetics of Development section, and on the G3: Genes|Genomes|Genetics board, we welcome Polly Campbell, Kevin Vogel, Joe Parker, and Ricardo Mallarino. Ricardo Zayas Associate Editor Ricardo Zayas is a Professor of Biology at…
-
Worms and Flies Provide Key Clues to Medical Mystery
This article is part of a series of posts outlining the history and impact of research in experimental organisms. The series is developed in collaboration with the GSA Public Communications and Engagement Committee. By the time Bertrand Might was six months old, it was clear something was amiss. His muscles weren’t developing normally; he was…
-
Congratulations to the 2023 Early Career Leadership Program Cohort!
The Genetics Society of America (GSA) is excited to announce the latest cohort of student, postdoc, and early-career research leaders joining the Early Career Leadership Program. Participants receive training and mentoring while serving on committees charged with understanding the needs, interests, concerns, and challenges of early career scientist members of the GSA. As part of…
-
GSA LOCI: Local Outreach Community Initiatives @ GSA Conferences
Highlights: Local Outreach Community Initiatives (LOCI): The Genetics Society of America is committed to supporting the communities of the host cities of our conferences. This new year, we are excited to reconnect with our GSA community in meaningful ways within and beyond our existing programming. The GSA membership has created a caring and supportive environment…
-
New members of the GSA Board of Directors: 2023–2025
We are pleased to announce the election of five new leaders to the GSA Board of Directors: 2023 Vice President/2024 President Mariana Wolfner Distinguished Professor of Molecular Biology and Genetics and Stephen H. Weiss Presidential Fellow My research has focused on the genes and pathways that mediate sexual development and reproduction, primarily in Drosophila. From…
-
Lance David Miller: Lighting Your Own Fire by Finding the Right Resources
By Daniel J. Gironda In the Paths to Science Policy series, we talk to individuals who have a passion for science policy and are active in advocacy through their various roles and careers. The series aims to inform and guide early career scientists interested in science policy. This series is brought to you by the…
-
Graça Almeida-Porada: The Importance of Communication in a Technologically Advancing World
By Daniel J. Gironda In the Paths to Science Policy series, we talk to individuals who have a passion for science policy and are active in advocacy through their various roles and careers. The series aims to inform and guide early career scientists interested in science policy. This series is brought to you by the…